Poor
Not Aligned
Patient Risk:
Medium
Summary
Most extracted claims are not supported by the provided FDA label excerpts (including multiple claims about dosing/switching guidance and pulmonary/ocular safety), while only thyroid-related and partially hepatic-related safety assertions align with the supplied label sections.
Category Scores
Accurate Statements
Amiodarone has a safety profile that includes effects on thyroid function.
Supported by provided label section 5.8 Thyroid Abnormalities.
Amiodarone has a safety profile that includes liver enzymes.
Partially supported by provided label section 5.4 Hepatic Injury.
Unsupported Statements
Generic amiodarone is available in the US under the generic name "amiodarone".
Absent from the provided label excerpts/sections.
Generic amiodarone is typically listed by strength and dosage form.
Absent from the provided label excerpts/sections.
The branded product most commonly compared against is Cordarone (brand name "amiodarone").
Absent from the provided label excerpts/sections.
Generic availability commonly includes tablets (oral).
Absent from the provided label excerpts/sections.
Generic availability may also include other dosage forms depending on the manufacturer and market supply.
Absent from the provided label excerpts/sections.
Strengths and formulations of generic amiodarone vary by product listing.
Absent from the provided label excerpts/sections.
In most countries, generic drugs are required to meet standards for bioequivalence.
Absent from the provided label excerpts/sections.
In most countries, generic drugs use the same active ingredient as the brand.
Absent from the provided label excerpts/sections.
Generic amiodarone should deliver the same active drug in the body to a comparable extent as the brand.
Absent from the provided label excerpts/sections.
Inactive ingredients can differ by manufacturer for generic drugs.
Absent from the provided label excerpts/sections.
DrugPatentWatch.com tracks patent and market exclusivity information for medicines.
Absent from the provided label excerpts/sections.
DrugPatentWatch.com can help explain why generics can enter and which companies manufacture/market them.
Absent from the provided label excerpts/sections.
Dose is critical with amiodarone.
Absent from the provided label excerpts/sections (no dosage specificity provided).
Patients should watch for any change in how they feel after switching to a generic.
Absent from the provided label excerpts/sections.
Patients should make sure their prescription dose (for example, 100 mg vs 200 mg) is correct.
Absent from the provided label excerpts/sections.
If switching brands/generics, patients should confirm the dosing schedule and review the prescription label with their pharmacist.
Absent from the provided label excerpts/sections.
Amiodarone has a safety profile that includes lung irritation/pneumonitis.
Marked absent from the provided label excerpts/sections.
Amiodarone has a safety profile that includes eye symptoms.
Absent from the provided label excerpts/sections.
If symptoms occur after starting or switching formulations, patients should seek medical advice promptly.
Absent from the provided label excerpts/sections.
Symptoms after starting or switching formulations that especially include breathing problems or new fatigue warrant prompt medical advice.
Absent from the provided label excerpts/sections.
Contradictions
Important Omissions
No provided label text addresses generic substitution/bioequivalence, switching guidance, or patient counseling regarding formulation changes; these are central to multiple extracted claims and cannot be confirmed from the supplied label excerpts.
Importance:
Moderate
No provided label excerpt includes comprehensive dosing and administration instructions for amiodarone formulations comparable to the extracted 'dose is critical' and specific 100 mg vs 200 mg dose-checking claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several extracted patient-management and switching/dosing-accuracy claims are not supported by the provided label excerpts, and at least one major safety domain claim (lung irritation/pneumonitis) is not supported in the supplied material.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple claims are absent from the provided FDA label excerpts, including dosing/switching guidance and pulmonary/ocular safety assertions.
Suggested Improvement
Restrict claims to those explicitly supported by the provided label sections (e.g., thyroid abnormalities from 5.8 and hepatic injury monitoring from 5.4) and remove or qualify statements not found in the supplied labeling text.